Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
boston blog main
boston top stories
national top stories
new york
new york blog main
new york top stories
parkinson's disease
san diego blog main
san diego top stories
abbvie
acorda therapeutics
akcea therapeutics
ampyra
anylam pharmaceuticals
apokyn
apomorphine
bial
biotech
cardiomyopathy
dalfampridine
drug development
drugs
duopa
fda
inbrija
inotersen
mylan
neurocrine
neurodegeneration
neuropathy
neuroscience
onpattro
opicapone
patisiran
paul matteis
pfizer
san diego
What
disease
3
×
fda
3
×
patients
3
×
approved
drug
gets
nod
parkinson’s
acorda
add
ago
akcea
alnylam
amyloidosis
attr
available
battle
called
carbidopa
combination
control
cope
daily
debilitating
episodes
experience
friday
genetic
help
late
levodopa
looms
meant
medication
medications
medicines
neurocrine
new
oks
pfizer
Language
unset
Current search:
fda
×
patients
×
disease
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms